Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

Edwards Lifesciences Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is ...

presented during the lat JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in ...

Edwards Lifesciences offers a broad range of treatments for heart failures via their PASCAL repair system, EVOQUE tricuspid replacement system, and the upcoming SAPIEN 3 mitral replacement system.

Leavell Investment Management Inc. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 3.3% ...

GSA Capital Partners LLP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) in the third ...

Piper Sandler analyst Adam Maeder maintained a Hold rating on Edwards Lifesciences (EW – Research Report) today and set a price target of ...